| Name | Title | Contact Details |
|---|
St. Ann`s Community is Rochester`s leading senior housing and health services provider, with a tradition of quality care for older adults dating back to 1873. St. Ann`s offers a continuum of care that includes independent retirement living, assisted living, skilled nursing, memory care, short-term transitional care, palliative care, and adult day programs. One of the area`s largest employers, St. Ann`s has more than 1,200 employees who are "Caring for the Most Important People on Earth."
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
The future of medical image management is in the cloud. Unfortunately, the farther data travels the more lag time accrues. We call this latency. Radiologists and other physicians are accustomed to receiving images at rates of 50 frames per second. When traveling across the entire United States, it may drop to 10 frames per second - much too slow for acceptable patient care. NucleusHealth™ overcomes latency via our patent-pending streaming protocols, client-side rendering techniques, modern web browser technologies, and the computing horsepower of todays phones, laptops and desktops. Diagnostic quality images come to life on displays at blazing-fast speeds. Even large file types such as digital breast tomosynthesis can be displayed in seconds, not minutes. With that single achievement, NucleusHealth sets a new standard for performance, scalability, security, high availability and response times. Faster, more accurate care means better outcomes at a lower cost. The next generation of medical image management has been born.
Hometrak is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Elementis Specialties (RHEOX) is a Hightstown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.